What is the history of Antithrombin III deficiency?

Antithrombin III deficiency was first clinically described in 1965 by Dr. Olav Egeberg, who identified a family with a high incidence of venous thromboembolism and a corresponding lack of blood-clotting regulation. Since that discovery, our understanding of Antithrombin III deficiency has evolved from a simple observation of hereditary clotting to a complex field of molecular genetics and targeted protein replacement therapies.

Who first discovered Antithrombin III deficiency?

The medical history of Antithrombin III deficiency began in Norway in 1965. Dr. Olav Egeberg, a researcher at the University of Oslo, studied a family plagued by recurrent, life-threatening blood clots. He identified that these patients possessed significantly lower levels of the plasma protein antithrombin, which acts as the body’s primary natural anticoagulant. Before this landmark study, recurrent clotting disorders were often misdiagnosed as generalized "thrombophilia" without a clear biological mechanism. Egeberg’s work shifted the paradigm, proving that a specific protein deficiency could be the underlying cause of hypercoagulability.

How has our understanding of the condition evolved?

In the decades following the initial discovery, the medical community moved from observing the clinical symptoms of Antithrombin III deficiency to understanding its molecular architecture. By the 1970s and 80s, researchers began to differentiate between Type I deficiency (a quantitative reduction in protein) and Type II deficiency (a qualitative defect where the protein is present but dysfunctional). This distinction was a major milestone, as it explained why some patients with normal protein levels still experienced severe clotting events. Today, we know that Antithrombin III deficiency is typically inherited in an autosomal dominant pattern, often caused by mutations in the SERPINC1 gene.

What are the major milestones in treatment development?

The management of Antithrombin III deficiency has progressed through several distinct eras:

• The Pre-Concentrate Era: Treatment relied solely on long-term anticoagulation (e.g., warfarin or heparin), which carried high risks of bleeding complications.


• The Introduction of Replacement Therapy: In the 1980s and 90s, plasma-derived antithrombin concentrates became available, allowing clinicians to provide "replacement therapy" during surgeries, childbirth, or acute clotting events.


• The Recombinant Era: In 2006, the FDA approved the first recombinant human antithrombin, produced from the milk of transgenic goats, significantly reducing the risk of viral transmission associated with human plasma.

How have modern genetics and advocacy changed the landscape?

Modern genomic sequencing has transformed the diagnosis of Antithrombin III deficiency, allowing for rapid identification of specific mutations that predict clinical severity. Concurrently, patient advocacy has grown significantly. With 42 people with Antithrombin III deficiency currently sharing their experiences on DiseaseMaps.org, the community has moved from isolated patient groups to a global network. This collective data helps researchers understand the real-world burden of the disease, moving beyond clinical statistics to address the psychological and daily impacts of living with a chronic clotting disorder.

Next steps

• Consult a hematologist specializing in coagulation disorders to discuss your specific protein levels and genetic profile.


• Connect with the 42 members of the DiseaseMaps.org community to share lived experiences and coping strategies.


• Work with a genetic counselor to understand the implications of Antithrombin III deficiency for family members and future planning.


• Monitor for updates on clinical trials via NIH clinicaltrials.gov regarding novel anticoagulants.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Antithrombin deficiency.


• Orphanet: Hereditary antithrombin deficiency (ORPHA:93).


• OMIM (Online Mendelian Inheritance in Man): Antithrombin III deficiency (Entry #613118).


• Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965.